Wound Gel Market Size To Reach $9.68 billion By 2033

 The global wound gel market size was valued at USD 6.05 billion in 2024 and is projected to reach USD 9.68 billion by 2033, growing at a CAGR of 5.37% from 2025 to 2033. The demand for wound gel is rising owing to the increasing number of surgical cases and the growing burden of wounds.

The rising number of surgical procedures worldwide is a significant driver for expanding the wound gels market. Surgical interventions often result in acute wounds that require effective post-operative care to minimize infection risk and promote faster healing. Advanced wound care products, particularly wound gels, are increasingly preferred due to their ability to maintain a moist wound environment, support autolytic debridement, and accelerate tissue regeneration. According to data published in the BMC Surgery journal in 2025, approximately 313 million surgical procedures are performed globally annually. This substantial volume underscores the growing demand for reliable and effective wound care solutions, reinforcing the critical role of wound gels in the post-surgical healing process.

List of Key Players in the Wound Gel Market

• Medline Industries, LP.
• Coloplast Ltd
• Mölnlycke Health Care AB
• Solventum
• Convatec Inc.
• Smith+Nephew
• B. Braun SE
• DermaRite Industries, LLC.
• Integra LifeSciences Corporation
• Axio Biosolutions Private Limited
• Sanara MedTech Inc

Request a free sample copy or view report summary: Wound Gel Market

Wound Gel Market Report Highlights

• The dressings segment dominated the wound gel industry in 2024, driven by continuous innovation in advanced materials such as hydrogel, gelling fiber, and specialty formulations like honey and silicone gel dressings.
• The silver (Ag+) segment held the largest market share in 2024 within the antimicrobial properties segment, demonstrating its leading role in advanced wound care. It is also anticipated to grow fastest over the forecast period.
• The chronic wounds segment dominated the market in 2024, capturing the largest share of 55.29%. This dominance is attributed to the high prevalence and significant healthcare burden associated with chronic wounds. 
• The offline segment held the largest market share in 2024. This dominance is primarily attributed to the widespread availability of wound gel products through hospitals, pharmacies, and medical supply stores, where healthcare professionals often guide product selection.
• The hospital segment dominated the market in 2024, accounting for the largest share of 41.52%. This dominance is due to the high volume of patients requiring advanced wound care for acute and chronic conditions.

Wound Gel Market Segmentation

Grand View Research has segmented the global wound gel market report based on product, antimicrobial properties, application, mode of purchase, distribution channel, end use, and region:

 

·         Product Outlook (Revenue, USD Million, 2021 - 2033)

• Dressings

• Hydrogel dressing
• Gelling fiber dressings
• Others
• Gels
• Antimicrobial Properties Outlook (Revenue, USD Million, 2021 - 2033)
• Silver (Ag+)
• Non-Silver
• Mode of Purchase Outlook (Revenue, USD Million, 2021 - 2033)
• Prescription
• Non-prescription
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Offline
• Online
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Chronic Wounds
• Diabetic Foot Ulcers (DFUs)
• Pressure Ulcers

• Stage 1
• Stage 2
• Stage 3
• Stage 4
• Leg Ulcers
• Acute Wounds
• Surgical Incisions
• Burns
• 1st Degree
• 2nd Degree
• 3rd Degree
• Lacerations, Abrasions
• End Use Outlook (Revenue, USD Million, 2021-2033)
• Hospitals
• Specialty Clinics
• Ambulatory Surgery Centers
• Homecare Settings
• Long-Term Care Facilities
• Others
• Regional Outlook (Revenue, USD Million, 2021-2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Recent Developments

In March 2025, SolasCure announced the enrollment of the first patient in its upcoming Phase II clinical trial to advance the development of the Aurase Wound Gel. This marks a significant milestone in the company’s efforts to evaluate the safety and efficacy of the gel in promoting wound healing. The trial is designed to gather critical data supporting further clinical development and potential regulatory approval of this innovative treatment.

In March 2025, Mölnlycke Health Care completed the acquisition of the manufacturer of Granudacyn. Granudacyn includes solutions and gels designed explicitly for wound cleansing, irrigation, and moisturizing across various wound types. This strategic acquisition strengthens Mölnlycke’s portfolio, enhancing its capabilities to deliver comprehensive and effective solutions for wound care and infection prevention.

 

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

AI In Blood Pressure Monitoring Market Insights and Forecast By 2030

 The global AI in blood pressure monitoring market size was estimated at USD 932.52 million in 2024 and is projected to reach USD 4.38 billion by 2030, growing at a CAGR of 29.98% from 2025 to 2030. Rising prevalence of hypertension and cardiovascular diseases, increasing demand for continuous and non-invasive monitoring, and growing consumer adoption of smart health devices are significant factors contributing to market growth.

Furthermore, advancements in AI & sensor technologies fuel market growth. Innovations in machine learning, edge computing, and biosensor miniaturization have significantly enhanced the accuracy and reliability of blood pressure estimation. AI can identify patterns and anomalies across vast data sets, allowing for personalized insights and predictive alerts, which improve user engagement and clinical decision-making. AI-powered monitoring systems use photoplethysmography (PPG) sensors to measure blood pressure, oxygen saturation, etc. For instance, in August 2024, Bisam Pharmaceuticals launched Quick Vitals, an AI and deep learning-powered health monitoring app in Hyderabad, India. This app uses Photoplethysmography (PPG) technology for rapid, accurate vital sign assessments such as heart rate, blood pressure, SPO2, etc., via smartphones or tablets in seconds.

In addition, the healthcare industry's adoption of AI-powered wearables is expanding rapidly. AI enhances its utility by analyzing large volumes of physiological data to detect anomalies, predict health risks, and enable timely interventions. This improves patient outcomes and reduces the burden on healthcare systems by minimizing hospital visits and enabling telehealth services. For instance, in June 2024, Sky Labs launched CART BP, a smart ring for continuous blood pressure monitoring. The ring provides real-time, non-invasive blood pressure tracking using advanced sensors and AI algorithms.

Request a free sample copy or view report summary: AI In Blood Pressure Monitoring Market Report

 

List of Key Players in the AI In Blood Pressure Monitoring Market

• Withings
• Aktiia SA
• Biospectal SA
• Valencell, INC.
• Biofourmis
• Edwards Lifesciences Corporation (now BD)
• Hello Heart
• FaceHeart Corporation
• Shen AI
• Huawei Technologies Co., Ltd.

Key Market Trends & Insights

·        North America AI in blood pressure monitoring market accounted for the largest revenue share of over 49% in 2024.

·        The U.S. AI in blood pressure monitoring market held the largest market share in 2024.

·        By end use, the hospitals & acute care segment held the largest market share of over 39% in 2024.

·        By application, the hypertension management segment accounted for the largest revenue share of over 37% in 2024.

·        By technology, the machine learning segment accounted for the largest revenue share of over 51% in 2024.

Recent Developments

• In May 2025, Hyderabad-based Niloufer Hospital launched AmruthSwasthBharath, an AI-based diagnostic tool for non-invasive blood testing. This device provides results in under a minute, utilizing Remote Photoplethysmography (PPG) to measure key health parameters such as blood pressure, heart rate, SpO2, respiration rate, and hemoglobin A1c via smartphones.
• In April 2025, BD introduced the HemoSphere Alta platform, an advanced hemodynamic monitoring solution featuring AI-driven algorithms. This technology assists clinicians in managing blood pressure instability and optimizing blood flow during critical situations. Key innovations include the Cerebral Autoregulation Index and the Acumen Hypotension Prediction Index, enhancing patient care and outcomes.

"HemoSphere Alta marks the latest milestone in our continuum of connected care innovations by redefining the clinician experience with more efficient workflows and increased usability. These AI-driven enhancements of advanced algorithms and machine learning provide clinicians with more insights and clinical decision support to help improve the quality of care for their patients."

- Tim Patz, president of BD Advanced Patient Monitoring

• In February 2025, Validic launched a generative AI-powered assistant for remote patient monitoring (RPM) using generative AI (GenAI) within its Validic Impact platform. Utilizing Generative AI, the solution automatically analyzes variations in vital health metrics such as blood glucose levels, blood pressure, medication adherence, and lifestyle factors, delivering clinicians insights between patient evaluations.
• In June 2024, Wellth, a digital health startup, enhanced its app with AI-driven, personalized, predictive features for blood pressure management. The app analyzes user-submitted blood pressure photos, provides tailored alerts, and incentivizes healthy behaviors.
• In July 2021, Zepp Health unveiled a new smartwatch OS that measures blood pressure using its PumpBeats algorithm, powered by the Huangshan 2s AI chip and biosensors.  

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Veterinary Imaging Market by IDEXX Laboratories, Inc.; Esaote SPA; Antech Diagnostics, Inc.; General Electric Company; Midmark Corporation

 The global Veterinary Imaging Market size is estimated to reach USD 3.87 billion by 2033, expanding at a CAGR of 7.17% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market growth can be attributed to the rising penetration of diagnostic imaging technology in therapeutic applications in pets and livestock animals. Moreover, rising pet ownership and humanization, rising incidence of zoonotic disease in animals, increased focus on preventive healthcare, advancements in technology, and rising awareness and education.

The increasing trend of pet humanization and ownership across different countries has led to a rise in pet insurance enrollment rates across the globe. Radiography is one of the most common diagnostic tests covered by pet insurance. Thus, growing adoption of pet insurance and increasing awareness of the various diagnostic & treatment options available for pets are some of the factors driving the market growth. For instance, as per North American Pet Health Insurance Association (NAPHIA) data published in 2023, the overall number of pets insured by the end of 2023 in the U.S. was 5.36 million. This reflects an increase in several diagnostic imaging performed on pets in veterinary hospitals across the U.S.

In addition, an increase in product launches for small animal diagnostic imaging is expected to drive the segment growth. For instance, in June 2023, Sunset Vet introduced the first Veterinary Computed Tomography (CT) service in Indonesia, aiming to revolutionize small animal veterinary imaging. With advanced technology, including high-resolution imaging and rapid, noninvasive procedures, Sunset Vet offers precise diagnoses and tailored treatment plans. Similarly, in June 2023, iCRco, Inc. installed its CLARIS V Cone Beam Computed Tomography (CBCT) imaging device at the Santa Barbara Zoo, marking its 4th anniversary. This advanced technology facilitates precise 3D imaging of exotic animals, enhancing veterinary care through noninvasive and efficient diagnosis. The collaboration underscores the zoo's commitment to leveraging cutting-edge veterinary imaging solutions for the welfare of small animals.

List of Key Players in Veterinary Imaging Market

• IDEXX Laboratories, Inc.
• Esaote SPA
• Antech Diagnostics, Inc.
• General Electric Company
• Midmark Corporation
• FUJIFILM Holdings America Corporation
• Hallmarq Veterinary Imaging
• CANON MEDICAL SYSTEMS EUROPE B.V.
• Shenzhen Mindray Animal Medical Technology Co., LTD
• Siemens Healthcare Limited

Request a free sample copy or view report summary: Veterinary Imaging Market Report

Veterinary Imaging Market Report Highlights

• In terms of product, the X-ray segment held the largest revenue share of 37.84% in 2024. X-ray is one of the most common diagnostic tests covered by pet insurance. Thus, rising pet insurance adoption and increased awareness of the various radiographic imaging solutions available for pets are contributing to segment growth.
• In 2024, the small animals segment accounted for the largest share of the market by animal type and is expected to witness the fastest CAGR over the forecast period due to an increase in pet population, growing adoption of pet insurance, and increasing product launches.
• Based on solution, the equipment segment dominated the global market with a share of 55.87% in 2024. On the other hand, the PACS segment is expected to witness the fastest CAGR over the forecast period.
• Based on application, the Orthopedics and Traumatology segment dominated the global market with a share of 37.91% in 2024. On the other hand, the oncology segment is expected to witness the fastest CAGR over the forecast period.
• Based on end use, the veterinary hospitals & clinics segment dominated the global market with a share of 59.16% in 2024 and is expected to witness the fastest CAGR over the forecast period.
• The North America region dominated the global market with a share of 39.28% in 2043. North America has a highly developed veterinary healthcare infrastructure with numerous clinics, hospitals, and specialty centers equipped with advanced diagnostic and treatment capabilities. This advanced infrastructure enables veterinarians to diagnose and manage conditions like joint diseases (such as osteoarthritis) and ligament injuries in animals more effectively, leading to a higher demand for veterinary imaging.
• Asia Pacific is expected to witness the fastest CAGR over the forecast period due to growing pet ownership rates, increasing awareness of veterinary imaging services, and growing strategic activities between key players to expand geographic footprints.

Veterinary Imaging Market Segmentation

Grand View Research has segmented the global veterinary imaging market based on product, type, animal type, application, modality, end use, and region:

Veterinary Imaging Product Outlook (Revenue, USD Million, 2021 - 2033)

• Equipment
• Accessories/ Consumables
• Software

Veterinary Imaging Type Outlook (Revenue, USD Million, 2021 - 2033)

• X-ray
• Ultrasound
• MRI
• CT Imaging
• Video Endoscopy

Veterinary Imaging Animal Type Outlook (Revenue, USD Million, 2021 - 2033)

• Small Animals
• Large Animals

Veterinary Imaging Application Outlook (Revenue, USD Million, 2021 - 2033)

• Orthopedics and Traumatology
• Oncology
• Cardiology
• Neurology
• Respiratory
• Dental Applications
• Others

Veterinary Imaging Modality Outlook (Revenue, USD Million, 2021 - 2033)

• Fixed
• Portable

Veterinary Imaging End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Veterinary Hospitals and Clinics
• Specialty Imaging Centers
• Others

Veterinary Imaging Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Rest of Europe
• Asia Pacific
• Japan
• India
• China
• South Korea
• Australia
• Thailand
• Rest of APAC
• Latin America
• Brazil
• Argentina
• Rest of LATAM
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Rest of MEA

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Blood Cancer Diagnostics Market: Industry Demand, Analysis And Future Trends 2030

 

The global Blood Cancer Diagnostics Market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.

Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company’s capabilities in this critical area of research.

Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.

Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.

Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care. 

List of Key Players in the Blood Cancer Diagnostics Market

• Quest Diagnostics
• Illumina
• InVivoScribe
• Ipsogen (Qiagen)
• Asuragen(Bio-Techne)
• Danaher Corporation
• Abbott
• Sequenta (Adaptive biotechnologies)
• SkylineDx
• Bio-Rad Laboratories
• Alercell
• Sophia Genetics

Request a free sample copy or view report summary: Blood Cancer Diagnostics Market Report

Blood Cancer Diagnostics Market Report Highlights

• Based on product, the assay kits and reagents accounted for the largest revenue share of the blood cancer diagnostics market in 2024. This high share is attributable to assay kits & reagents being designed to detect specific biomarkers, genetic mutations, and other indicators, enabling healthcare professionals to diagnose & treat the disease more effectively
• Based on tests, blood tests segment dominated the market and accounted for the largest share in 2024. This can be attributed to increasing innovation and availability of blood test kits for blood cancer detection

• Based on end use, hospitals and clinics dominated the market with the largest share of blood cancer diagnostics market in 2024. This is attributable to growing demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, blood typing. Furthermore, Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services in their settings

• North America dominated the market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like leukemia These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies
• Asia Pacific is expected to witness the fastest growth over the forecast period from 2025 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities

Blood Cancer Diagnostics Market Segmentation 

Grand View Research has segmented the global blood cancer diagnostics market based on product, test, end-use, and region:

Blood Cancer Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments
• Assay Kits and Reagents

Blood Cancer Diagnostics Test Outlook (Revenue, USD Million, 2018 - 2030)

• Blood Tests
• Imaging Tests
• Biopsy
• Molecular Test

Blood Cancer Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals and Clinics
• Diagnostic Labs
• Research Institutes

Blood Cancer Diagnostics Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Sweden
• Denmark
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa
• Saudi Arabia
• South Africa
• UAE
• Kuwait

About Us
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Postpartum Depression Drugs Market: Industry Demand, Analysis And Future Trends 2030

 The global Postpartum Depression Drugs Market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period, according to a new report by Grand View Research, Inc. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.

According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July 2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.

Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.

Request a free sample copy or view report summary: Postpartum Depression Drugs Market Report

Postpartum Depression Drugs Market Report Highlights

• The postpartum anxiety segment held the largest share of the market in 2023. This can be attributed to the disease's high treatment rate and growing prevalence in developed and developing countries.
• Based on the treatment type, the hormonal therapy segment is expected to grow at the fastest CAGR during the forecast period.This can be attributed to the development and commercialization of new hormonal drugs and increased adoption by smaller hospitals and facilities for the treatment of PDD.
• In 2023, the oral segment held the largest share of the market based on the route of administration. This dominance can be attributed to the increase in the prevalence and incidence of disease worldwide, the large availability of products, and the rising demand for new generic oral drugs for treatment.
• The hospital pharmacy segment held the largest share of the market based on distribution channels in 2023. Hospital treatment rates, patient preference for hospitals over other healthcare settings for PDD treatment, and the increasing number of patients visiting hospitals.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.

Postpartum Depression Drugs Market Segmentation

Grand View Research has segmented the postpartum depression drugs market based on type, treatment, route of administration, distribution channel, and region:

Postpartum Depression Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Postpartum Blues
• Postpartum Anxiety
• Postpartum Obsessive-Compulsive Disorder (OCD)
• Postpartum Post-Traumatic Stress Disorder (PTSD)
• Postpartum Panic Disorder
• Postpartum Psychosis

Postpartum Depression Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmacotherapy
• Hormonal Therapy
• Others

Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Parenteral
• Oral
• Others

Postpartum Depression Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy
• Retail Pharmacy
• Others (online pharmacy)

Postpartum Depression Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• Kuwait
• UAE

About Us
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com